Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2021

View Archived Issues

Health Canada approves clinical trials of AT-1501 in kidney transplantation

Interim update on first-in-human study of SB-11285 in solid tumors

PolarityTE submits IND for SkinTE in chronic cutaneous ulcers

Yeast study reveals potential cancer therapy approach

Japan Tobacco divulges new NLRP3 inflammasome inhibitors

Beijing Scitech-Mq Pharmaceuticals identifies new FGFR4 inhibitors

New DGAT-2 inhibitors discovered at LG Chem

Ophirex initiates phase II study of varespladib in severe COVID-19

Jiangsu Simcere Pharmaceutical R&D describes TGF-beta receptor type-1 inhibitors

Cerecor reports initial phase Ib data on CERC-002 in moderate to severe Crohn's disease

Leo Pharma begins phase IIa study of LEO-138559 for moderate to severe atopic dermatitis

XWPharma starts first-in-human study of XW-10508

Inozyme opens enrollment in phase I/II study of INZ-701 for ENPP1 deficiency

Responses seen with personalized neoantigen peptide vaccine in NSCLC patients with EGFR mutations

Enrollment opens in phase I study of BI-1569912 for major depressive disorder

Inhalable human ACE2-containing nanocatchers may protect host cells from SARS-CoV-2 infection

First-in-human safety and PK data reported for pirepemat

Xenon Pharmaceuticals targets Nav1.5 with aryl sulfonamide inhibitors

Grunenthal begins phase I trial of glucocorticoid receptor modulator